+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test (Bone Marrow Examination, Complete Blood Count Test, Flow Cytometry), Treatment (Blood Transfusion, Medication, Stem Cell Transplant) - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968573
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Paroxysmal Nocturnal Hemoglobinuria Treatment Market size was estimated at USD 3.15 billion in 2023, USD 3.49 billion in 2024, and is expected to grow at a CAGR of 10.88% to reach USD 6.51 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics, PLC, Alexion Pharmaceuticals, Inc. by AstraZeneca PLC, Alnylam Pharmaceuticals, Inc., Amgen Inc., Amyndas Pharmaceuticals, Apellis Pharmaceuticals, Inc., CinnaGen Co., F. Hoffmann-La Roche AG, Novartis AG, Ra Pharma by Cohance Lifesciences, Regeneron Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Paroxysmal Nocturnal Hemoglobinuria Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diagnostic Test
    • Bone Marrow Examination
    • Complete Blood Count Test
    • Flow Cytometry
    • Lactate Dehydrogenase Test
    • Urine Test for Hemosiderin
  • Treatment
    • Blood Transfusion
    • Medication
    • Stem Cell Transplant
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
  4. What is the market share of the leading vendors in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Paroxysmal Nocturnal Hemoglobinuria Treatment Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing adoption of novel therapeutics
5.1.1.2. Rising geriatric population and the emergence of biologics
5.1.1.3. Growing number of blood and bone marrow related disorders
5.1.2. Restraints
5.1.2.1. High costs associated with medical treatment
5.1.3. Opportunities
5.1.3.1. Increasing development in stem cell research
5.1.3.2. Rising investment in research & development of PNH treatment drugs
5.1.4. Challenges
5.1.4.1. Adverse side effects with existing treatments
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Diagnostic Test
6.1. Introduction
6.2. Bone Marrow Examination
6.3. Complete Blood Count Test
6.4. Flow Cytometry
6.5. Lactate Dehydrogenase Test
6.6. Urine Test for Hemosiderin
7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment
7.1. Introduction
7.2. Blood Transfusion
7.3. Medication
7.4. Stem Cell Transplant
8. Americas Paroxysmal Nocturnal Hemoglobinuria Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Akari Therapeutics, PLC
12.1.2. Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
12.1.3. Alnylam Pharmaceuticals, Inc.
12.1.4. Amgen Inc.
12.1.5. Amyndas Pharmaceuticals
12.1.6. Apellis Pharmaceuticals, Inc.
12.1.7. CinnaGen Co.
12.1.8. F. Hoffmann-La Roche AG
12.1.9. Novartis AG
12.1.10. Ra Pharma by Cohance Lifesciences
12.1.11. Regeneron Pharmaceuticals, Inc.
12.1.12. Samsung Bioepis Co., Ltd.
12.1.13. Thermo Fisher Scientific Inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET DYNAMICS
FIGURE 7. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2023 VS 2030 (%)
FIGURE 8. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 6. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BONE MARROW EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLETE BLOOD COUNT TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LACTATE DEHYDROGENASE TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY URINE TEST FOR HEMOSIDERIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 12. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 23. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 25. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 33. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 35. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 37. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 39. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 41. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 43. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 45. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 47. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 49. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 51. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 53. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 55. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 60. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 62. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 64. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 66. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 68. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 70. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 72. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 74. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 76. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 78. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 80. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 82. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 86. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 90. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 92. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 94. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 96. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 102. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 103. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Akari Therapeutics, PLC
  • Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amyndas Pharmaceuticals
  • Apellis Pharmaceuticals, Inc.
  • CinnaGen Co.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Ra Pharma by Cohance Lifesciences
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.49 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.51 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal

Related Topics

Related Reports

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Paroxysmal Nocturnal Hemoglobinuria Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 86 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Global Paroxysmal Nocturnal Hemoglobinuria Market - Product Image

Global Paroxysmal Nocturnal Hemoglobinuria Market

  • Report
  • 200 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From

About the Market

The Paroxysmal Nocturnal Hemoglobinuria (PNH) drug market is a specialized segment within the broader category of hematological drugs, which encompasses medications for a wide range of blood disorders. PNH is a rare, life-threatening blood disease characterized by the destruction of red blood cells, leading to hemoglobin release in the urine, particularly noticeable at night or in the early morning. Treatments for PNH focus on reducing hemolysis, preventing thrombosis, and improving quality of life. Historically, the management of PNH involved supportive treatments such as blood transfusions and iron therapy; however, the advent of novel targeted therapies has transformed the therapeutic landscape. These innovative drugs inhibit the complement system, which plays a central role in the pathophysiology of PNH. The development and approval of these complement inhibitors have provided patients with the first disease-specific treatments, substantially improving clinical outcomes. Several companies have made their mark in the PNH drug market, with a strong focus on research and development for more effective and patient-friendly treatments. Leading players include Alexion Pharmaceuticals, Inc., which developed eculizumab, a monoclonal antibody that has been a cornerstone in PNH treatment. Other notable companies operating in the space are Apellis Pharmaceuticals, which has made strides with its complement inhibitor pegcetacoplan, and Novartis, exploring gene-therapy approaches to provide long-term relief for patients afflicted by the disorder. These companies, along with others engaged in the Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.